LONDON, May 24, 2017 /PRNewswire/ --
ZIVEREL® designed to protect and repair oesophageal mucosa
Norgine B.V. today announced that ZIVEREL® is now available in Austria, Belgium, Luxembourg and Switzerland. ZIVEREL® is a Class III medical device for the protective treatment of the oesophageal mucosa. ZIVEREL® is currently the only liquid treatment designed to protect and repair the oesophagus, offering rapid relief from the symptoms of gastro-oesophageal reflux.
Gastro-oesophageal reflux disease is prevalent worldwide, and disease burden may be increasing. It affects up to 20% of the Western population and is associated with a range of risk factors.
Peter Martin, Chief Operating Officer, Norgine said, "We are pleased to make ZIVEREL® available in additional countries including Austria, Belgium, Luxembourg and Switzerland. This will ensure that patients have access to this important treatment. ZIVEREL® protects and repairs the gastro-oesophageal mucosa and offers prolonged relief from the symptoms of this burdensome condition."
ZIVEREL® is an over the counter product that does not require a medical prescription. Prices are applicable per market.
ZIVEREL® is already available from Norgine in Spain. Further launches of ZIVEREL® are anticipated throughout 2017.
Norgine has the commercialisation and distribution rights for ZIVEREL® in Australia, Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland and the UK.
View the full release on http://www.norgine.com
1. ZIVEREL® Instructions for Use, Sept. 2016
2. J Dent [http://gut.bmj.com/search?author1=J+Dent&sortspec=date&submit=Submit ] et al. Gut2005;54:710-717 doi:10.1136/gut.2004.051821. http://gut.bmj.com/content/54/5/710.full
Norgine Media Contacts
Isabelle Jouin, T: +44-(0)-1895-453-643
Charlotte Andrews, T: +44-(0)-1895-453-607
Follow us @norgine
SOURCE Norgine B.V.